Abstract
In this issue of Molecular Therapy, Barese and colleagues from the National Institutes of Health present a landmark study conducted in a clinically relevant large-animal model to evaluate the utility of the herpes simplex virus thymidine kinase (HSVtk) gene for conditional elimination of transplanted long-term repopulating hematopoietic cells, potentially representing true hematopoietic stem cells (HSCs).1 This paper provides proof of concept for this approach, is rich in highly relevant experimental findings, and presents a stimulating discussion that will certainly motivate the field to pay even more attention to the important principle of conditional negative selection of gene-modified cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
